Business context and reporting period
Oragenics, Inc. is a development-stage biotechnology company reporting for the quarter and nine months ended September 30, 2022. Its principal programs are NT-CoV2-1, an intranasal SARS-CoV-2 vaccine candidate, and preclinical lantibiotic antibiotic candidates. The company reported no product sales; revenue was grant revenue.
Financial results and liquidity
| Metric | Three months ended September 30, 2022 | Nine months ended September 30, 2022 |
|---|---|---|
| Grant revenue | $86,047 | $131,521 |
| Research and development expense | $2.825 million | $10.596 million* |
| General and administrative expense | $1.215 million | $3.591 million |
| Net loss | $3.918 million | $13.986 million |
| Basic and diluted loss per share | $0.03 | $0.12 |
At September 30, 2022, cash and cash equivalents were $13.951 million, total assets $15.041 million, working capital $13.015 million, and shareholders’ equity $13.338 million. The company had $424,924 in short-term notes payable and $406,566 in operating lease liabilities. No meaningful operating margin is available because revenue consisted of grants and the company had no product sales.
For the first nine months, operating cash use was $12.796 million, investing cash use was $112,081, and financing cash use was $406,921. Cash fell $13.315 million from year-end 2021. The filing says existing resources are expected to fund the current operating plan through the first quarter of 2023; management states there is substantial doubt about the company’s ability to continue as a going concern beyond that period without further financing.
Changes versus prior comparable periods
- Third-quarter net loss improved to $3.918 million from $4.384 million a year earlier; operating expenses declined 8.1%, with R&D lower and G&A higher.
- Nine-month net loss increased to $13.986 million from $13.419 million. R&D rose 14.2%, principally reflecting vaccine development activity; G&A decreased 14.4%.
- Grant revenue was $131,521 for the first nine months of 2022 versus none in the comparable 2021 period.
- Operating cash use increased to $12.796 million from $10.986 million. Unlike 2021, the company had no comparable financing inflow from common-stock sales and warrant exercises.
- In August 2022, holders converted 4.0 million Series A and 2.55 million Series B preferred shares into 910,003 common shares. Common shares outstanding were 117,304,809 at quarter-end.
Outlook, commentary, and risks
Management focused vaccine development on intranasal NT-CoV2-1. A GLP rabbit toxicology study had concluded, but the final report remained in preparation and was needed to support an IND filing. The company reported that the FDA indicated an IND could be filed after the final toxicology report is available. Management expected final results around year-end 2022 and planned to pursue Phase 1 development, subject to funding.
The lantibiotic program remained preclinical, supported in part by a $250,000 small-business innovation grant. The company expects research and development spending to increase as vaccine development advances, but says later development depends on additional funding, grants, partnerships, or licensing. It has no committed financing source. Financing may be unavailable or unfavorable; equity issuance could dilute shareholders, while inability to raise capital could force delays, reductions, or discontinuation of programs. The company was evaluating cost-saving measures that might extend cash runway through 2023, but gave no assurance those measures would be implemented or sufficient.
Other risks include clinical, manufacturing, regulatory and development uncertainty; competition from available COVID-19 vaccines; possible effects of the pandemic on operations and trials; and the terms and obligations of technology licenses. No material legal proceedings were reported. Management concluded disclosure controls were effective as of September 30, 2022 and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Cash runway and financing progress, including whether the stated first-quarter 2023 funding horizon or potential cost savings changed.
- Completion and contents of the final GLP toxicology report, IND submission status, and any subsequent FDA feedback or clinical-trial plans.
- Whether the $250,000 lantibiotic grant and other funding sources adequately support planned research.
- Potential dilution and capital structure, including preferred-stock conversion rights, outstanding warrants, and available shelf registration capacity.
- *The filing’s nine-month R&D amount is inconsistent: the financial statements and MD&A state $10,595,842, while an R&D detail table states $10,598,842. Confirm the correct figure against the filed financial statements.